Skip to main content

Table 2 Constitutive expression and increase of CD26 at the surface of human colorectal carcinoma cells by anticancer drugs

From: Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26

Cell line

Basal CD26 expression (cpm/105 cells)

Drug treatment

  

5-FU

Cis

Vin

MTX

  

Maximal increase (% over control)

HT-29

1,300 ± 140

30 ± 5.8**

72 ± 26***

41 ± 10**

26 ± 6.4**

T84

780 ± 69

84 ± 14*

61 ± 42

78 ± 6.6

73 ± 42

HRT-18

370 ± 64

17 ± 9.1*

19 ± 9.1

23 ± 12

18 ± 9.4**

SW480

55 ± 15

96 ± 58*

90 ± 66

100 ± 59**

170 ± 150

SW620

26 ± 12

36 ± 31

28 ± 30

45 ± 43

53 ± 49

  1. The relative basal cell-surface protein expression for each cell line was summarized from 12–5 independent experiments. Cells were treated with drugs (5-FU, 5-fluorouracil [0.1 – 1,000 μg/mL]; Cis, cisplatin [0.001 – 10 μg/mL]; Vin, vinblastine [0.001 – 10 μg/mL]; MTX, methotrexate [0.1 – 1,000 μg/mL]) and cell surface expression of CD26 was determined by radioimmunobinding assay 48 h later. Maximal up-regulation of CD26 was recorded from 3–7 independent dose–response experiments for each drug and cell line. Data are shown as mean % increases ± SE for the moderate/high CD26-expressing cell lines, and mean numerical increases (cpm/105 cells) ± SE for the low expressers. *, significant increase due to drug, P < 0.05; **, P < 0.01; ***, P < 0.001, using paired t-test